Purple Biotech 株価情報 (NASDAQ: PPBT)

最新ニュース Purple Biotech (NASDAQ:PPBT) 株価情報

Purple Biotech

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech Ltd

News

Trump Says He Wants To Bring Pharmaceuticals Back To America With Tariffs

Macro Economic Events

Economics

Trump Says We Will Put Tariffs On Chips And Oil And Gas, Says Oil And Gas Tariffs By Feb 18

Trump Says He Will Put Tariffs On Steel Aluminum And Copper

High-rolling investors have positioned themselves bearish on Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in NEM often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for Newmont. This is not a typical pattern.
The sentiment among these major traders is split, with 25% bullish and 62% bearish. Among all the options we identified, there was one put, amounting to $48,300, and 7 calls, totaling $629,680.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $35.0 to $50.0 for Newmont over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Newmont options trades today is 4342.12 with a total volume of 1,888.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Newmont's big money trades within a strike price range of $35.0 to $50.0 over the last 30 days.
<h3>Newmont Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738356893_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$10.8</td>
<td>$10.6</td>
<td>$10.7</td>
<td>$35.00</td>
<td>$181.8K</td>
<td>8.0K</td>
<td align="right">170</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$8.2</td>
<td>$7.8</td>
<td>$7.8</td>
<td>$45.00</td>
<td>$143.5K</td>
<td>423</td>
<td align="right">194</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$2.2</td>
<td>$2.19</td>
<td>$2.2</td>
<td>$47.50</td>
<td>$124.5K</td>
<td>7.5K</td>
<td align="right">587</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$3.15</td>
<td>$3.1</td>
<td>$3.15</td>
<td>$42.50</td>
<td>$69.9K</td>
<td>1.1K</td>
<td align="right">518</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.35</td>
<td>$5.25</td>
<td>$5.25</td>
<td>$47.50</td>
<td>$48.3K</td>
<td>2.8K</td>
<td align="right">9</td>
</tr>
</tbody>
</table>

<h3>About Newmont</h3>
Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 17 wholly or majority owned mines and interests in two joint ventures in the Americas, Africa, Australia and Papua New Guinea. The company is expected to produce roughly 5.5 million ounces of gold in 2024 from its core mines and 6.8 million in total. It is likely to sell a number of its higher cost, smaller mines accounting for 20% of forecast sales in 2024. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves along with significant byproduct reserves at the end of December 2023.
Following our analysis of the options activities associated with Newmont, we pivot to a closer look at the company's own performance.
<h3>Newmont's Current Market Status</h3>
<ul>
<li>Trading volume stands at 5,935,415, with NEM's price down by -1.31%, positioned at $42.52.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 20 days.</li>
</ul>
<h3>What Analysts Are Saying About Newmont</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $50.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Scotiabank has decided to maintain their Sector Perform rating on Newmont, which currently sits at a price target of $50. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Newmont with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Spotlight on Newmont: Analyzing the Surge in Options Activity

Whales with a lot of money to spend have taken a noticeably bearish stance on Roku.
Looking at options history for Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $336,767 and 4, calls, for a total amount of $132,900.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $125.0 for Roku, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Roku options trades today is 1433.43 with a total volume of 983.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Roku's big money trades within a strike price range of $60.0 to $125.0 over the last 30 days.
<h3>Roku 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738356888_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ROKU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$11.5</td>
<td>$11.45</td>
<td>$11.5</td>
<td>$85.00</td>
<td>$83.9K</td>
<td>666</td>
<td align="right">73</td>
</tr>
<tr>
<td>ROKU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$11.75</td>
<td>$11.4</td>
<td>$11.4</td>
<td>$85.00</td>
<td>$83.2K</td>
<td>666</td>
<td align="right">99</td>
</tr>
<tr>
<td>ROKU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$11.4</td>
<td>$11.3</td>
<td>$11.4</td>
<td>$85.00</td>
<td>$66.1K</td>
<td>666</td>
<td align="right">233</td>
</tr>
<tr>
<td>ROKU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.36</td>
<td>$2.35</td>
<td>$2.36</td>
<td>$105.00</td>
<td>$47.2K</td>
<td>6.1K</td>
<td align="right">18</td>
</tr>
<tr>
<td>ROKU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$17.9</td>
<td>$16.5</td>
<td>$17.78</td>
<td>$100.00</td>
<td>$35.5K</td>
<td>38</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h3>About Roku</h3>
Roku enables consumers to stream television programming. It has more than 80 million streaming households and provided well over 100 billion streaming hours in 2023. Roku is the top streaming operating system in the US, reaching more than half of broadband households, according to the company. Roku's OS is built into streaming devices and televisions that Roku sells and on connected televisions from other manufacturers that license Roku's name and software. Roku also operates the Roku Channel, a free, ad-supported streaming television platform that offers a mix of on-demand and live television programming. Roku generates revenue primarily from selling devices, licensing, and advertising, and it receives fees from subscription streaming platforms that sell subscriptions through Roku.
<h3>Roku's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 1,909,346, the ROKU's price is down by -2.61%, now at $83.05. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 13 days.</li>
</ul>
<h3>What Analysts Are Saying About Roku</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $97.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from JMP Securities downgraded its rating to Market Outperform, setting a price target of $95. 
&#x2A; Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $100.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Roku, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

ROKU

Roku Options Trading: A Deep Dive into Market Sentiment

After cutting the federal funds rate three straight times to end 2024, the Federal Reserve left <a href="https://www.benzinga.com/25/01/43316048/fed-holds-interest-rates-steady-halts-streak-of-consecutive-cuts-as-inflation-remains-elevated">rates unchanged in January</a>.
A new Benzinga reader poll asks which Magnificent 7 stock could be most hurt by the decision.
What Happened: The Fed kept the federal funds rate steady in January at 4.25% to 4.5%, a decision that comes after three straight cuts totaling 100 basis points in 2024.
Cutting interest rates can help make borrowing more affordable and can lead to economic growth.
The Magnificent Seven stocks are among the largest companies in the world and can sometimes be insulated from economic pressures. Better borrowing rates could be more attractive to some of the companies that sell more expensive items.
"Which Magnificent 7 stock will be most negatively impacted by the Fed's rate decision?" Benzinga asked.
The results were:
<ul>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>): 39%</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>): 30%</li>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>): 9%</li>
<li>Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>): 9%</li>
<li>Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>): 8%</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>): 5%</li>
<li>Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>): 0%</li>
</ul>
Tesla won the poll with 39% saying the stock would be impacted the worst by the Fed's decision. This is likely due to borrowing rates and Tesla having more expensive items than the other stocks. Ranking second was Nvidia, a company that likely benefits from other companies seeing growth as it supplies products to both companies and consumers.
The poll found Amazon, Microsoft, Apple and Meta having similar impacts based on readers' opinions.
Alphabet received no votes in the poll, which could suggest the company will benefit or not be negatively impacted at all by Fed rate cut decisions.
Read Also: <a href="https://www.benzinga.com/tech/25/01/43302711/nvidia-hardest-hit-among-mag-7-stocks-by-deepseek-and-this-stock-ranked-second">EXCLUSIVE: Nvidia Hardest Hit Among Mag 7 Stocks By DeepSeek, Poll Shows — And This Stock Ranked Second</a>
Why It's Important: With the Federal Reserve&#8217;s decision to keep rates steady,&nbsp;<a href="https://www.benzinga.com/25/01/43319060/first-rate-cut-in-june-if-at-all-in-2025-economist-says-as-federal-reserve-holds-rates-steady" target="_blank" rel="noreferrer noopener">economists now predict&nbsp;</a>that the first&nbsp;rate cut will not come until June or later, with a 30% chance in March, a 45% chance in June, and a 28% chance in September.
<a href="https://www.benzinga.com/25/01/43395891/was-feds-decision-to-keep-rates-steady-the-right-move-72-say">Benzinga also asked</a> if the Fed's decision was correct. The majority of readers (72%) said the Fed's decision to keep rates steady was the current one with 22% saying they should have cut rates and 5% saying the Fed should have raised rates.
The Fed&#8217;s statement said that &#8220;economic activity has continued to expand at a solid pace&#8221; and said inflation was moving closer to the 2% target. While the Fed talked positively about inflation progress, they noted that the metric &#8220;remains somewhat elevated,&#8221; which was less positive than comments at the December meeting.
President&nbsp;Donald Trump&nbsp;has been calling for more rate cuts and&nbsp;<a href="https://www.benzinga.com/news/25/01/43332996/trump-slams-feds-terrible-job-on-bank-regulation-after-rate-hold-vows-to-unleash-lending-for-all-ame" target="_blank" rel="noreferrer noopener">spoke out after</a>&nbsp;the Fed&#8217;s decision Wednesday.
&#8220;The Fed has done a terrible job on Bank Regulation,&#8221; Trump said in a post on Truth Social.
The president promised that his administration would &#8220;unleash lending for all American people and businesses.&#8221;
The next FOMC meeting is scheduled for March 18-March 19, which could see the Fed deciding to keep rates unchanged again or making another cut.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/01/43041374/exclusive-how-high-will-sp-500-go-under-donald-trump-in-2025-readers-are-optimistic-26-say-this">EXCLUSIVE: How High Will S&amp;P 500 Go Under Donald Trump In 2025? Readers Are Optimistic, 26% Say This…</a></li>
</ul>
The study was conducted by Benzinga from Jan. 29, 2025 through Jan. 30, 2025. It included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 89 adults.
Image: Shutterstock

Federal Reserve

Exclusives

Trading Ideas

AAPL

AMZN

GOOG

GOOGL

MSFT

NVDA

TSLA

EXCLUSIVE: This 'Magnificent 7' Stock Will Feel The Pinch Of Fed's Rate Decision, Poll Shows

Deep-pocketed investors have adopted a bearish approach towards Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AAPL usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 186 extraordinary options activities for Apple. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 43% leaning bullish and 44% bearish. Among these notable options, 51 are puts, totaling $3,320,832, and 135 are calls, amounting to $9,791,438.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $155.0 and $300.0 for Apple, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Apple stands at 9040.1, with a total volume reaching 2,841,022.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Apple, situated within the strike price corridor from $155.0 to $300.0, throughout the last 30 days.
<h3>Apple Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738356883_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$3.0</td>
<td>$2.98</td>
<td>$3.0</td>
<td>$240.00</td>
<td>$264.9K</td>
<td>11.8K</td>
<td>17.9K</td>
</tr>
<tr>
<td>AAPL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/31/25</td>
<td>$2.22</td>
<td>$2.15</td>
<td>$2.22</td>
<td>$240.00</td>
<td>$119.4K</td>
<td>10.9K</td>
<td>103.8K</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$20.65</td>
<td>$20.55</td>
<td>$20.55</td>
<td>$250.00</td>
<td>$102.7K</td>
<td>15.2K</td>
<td>414</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$4.55</td>
<td>$4.45</td>
<td>$4.45</td>
<td>$235.00</td>
<td>$89.1K</td>
<td>3.0K</td>
<td>6.0K</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$4.55</td>
<td>$4.4</td>
<td>$4.51</td>
<td>$235.00</td>
<td>$83.4K</td>
<td>9.2K</td>
<td>4.5K</td>
</tr>
</tbody>
</table>

<h3>About Apple</h3>
Apple is among the largest companies in the world, with a broad portfolio of hardware and software products targeted at consumers and businesses. Apple's iPhone makes up a majority of the firm sales, and Apple's other products like Mac, iPad, and Watch are designed around the iPhone as the focal point of an expansive software ecosystem. Apple has progressively worked to add new applications, like streaming video, subscription bundles, and augmented reality. The firm designs its own software and semiconductors while working with subcontractors like Foxconn and TSMC to build its products and chips. Slightly less than half of Apple's sales come directly through its flagship stores, with a majority of sales coming indirectly through partnerships and distribution.
Following our analysis of the options activities associated with Apple, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Apple</h3>
<ul>
<li>With a trading volume of 67,066,429, the price of AAPL is down by -1.45%, reaching $234.15.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 90 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Apple</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $241.866.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Jefferies has decided to maintain their Underperform rating on Apple, which currently sits at a price target of $202. 
&#x2A; An analyst from Barclays has decided to maintain their Underweight rating on Apple, which currently sits at a price target of $197. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Apple, targeting a price of $260. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Buy rating on Apple, which currently sits at a price target of $280. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Apple with a target price of $270. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Apple with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Apple Unusual Options Activity

WIIM

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are lower after Trump reiterated the Feb. 1 tariff deadline.

Trump Says Nothing Can Be Done By China, Mexico And Canada Right Now To Forestall Tariffs; Says We May Increase Tariffs, Not Looking For Concession

President Donald Trump went through with his plans to impose a 25% tariff on imports from Mexico. This tariff, along with that on Canada (25%) and China (10%), goes into effect on Saturday. This move is expected to impact companies that rely heavily on Mexican car parts. 
Automakers such as General Motors Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) export vehicles from its Mexican plant to North America, according to a Reuters report. The report also suggested that other U.S. auto manufacturers likely to take a hit are Ford Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) and Stellantis NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>), which are among the top U.S. producers in Mexico. 
Needless to say, <a href="https://www.benzinga.com/etfs">ETFs focusing on the automotive sector</a> are facing significant challenges. Here are three such ETFs that are in focus right now:
First Trust Nasdaq Transportation ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXR#NASDAQ">FTXR</a>): This ETF provides exposure to transportation companies, including major automakers and auto parts suppliers. Companies such as General Motors and Ford are part of its portfolio. According to a recent report by <a href="https://www.statista.com/statistics/898955/mexico-motor-vehicle-production-brand/#:~:text=In%202024%2C%20the%20number%20of,the%20American%20company%20General%20Motors.">Statista</a>, in 2024, &#8220;The number of light vehicles produced in Mexico reached nearly four million units, from which roughly 22.3% were produced by the American company General Motors.&#8221;
Firms such as Tesla, which announced a new plant in Nuevo León, Mexico, are among its holdings.
Global X Autonomous &amp; Electric Vehicles ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIV#NASDAQ">DRIV</a>): Focusing on the future of the auto industry, this fund includes companies involved in electric and autonomous vehicles. Ford is among the top holdings of this ETF.
iShares Self-Driving EV and Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDRV#NYSE">IDRV</a>): This ETF targets companies engaged in electric vehicles and self-driving technologies. It includes automakers and parts suppliers with operations in Mexico, such as Volkswagen, making it susceptible to the proposed tariffs. Notably, Volkswagen exported 109,735 light vehicles from Mexico to North America from January to July 2024, per the Mexican Automotive Manufacturers Association, as reported by Reuters.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43390001/feds-favorite-inflation-gauge-rises-as-predicted-consumer-spending-jumps">Fed&#8217;s Favorite Inflation Gauge Rises As Predicted, Consumer Spending Jumps At Fastest Pace In 9 Months</a>
<h1 class="wp-block-heading">Impact Of The Proposed Tariffs</h1>
In November last year, Bernstein analyst Daniel Roeska wrote in a note that Volkswagen, Stellantis, General Motors and Ford would be the hardest hit. "A 25% tariff on Mexico and Canada would severely cripple the U.S. auto industry," he said.
An earlier <a href="https://apnews.com/article/trump-tariffs-prices-inflation-mexico-canada-d44aa0715a649998195fc3211e9ab7a3">report </a>from the Associated Press said that General Motors imports approximately 30% of the vehicles it sells in the U.S. from Canada and Mexico. About 55% of their popular pickup trucks also are imported from Mexico and Canada. The bottom line of General Motors and other automakers are expected to be affected.
According to International Trade Administration, Mexico is the world&#8217;s seventh-largest passenger vehicle <a href="https://www.trade.gov/country-commercial-guides/mexico-automotive-industry#:~:text=Leading%20Sub%2DSectors%20and%20Opportunities,Tech%20Top%20Export%20Market%20Ranking.">manufacturer</a>, producing 3.5 million vehicles annually. Eighty-eight percent of vehicles produced in Mexico are exported, of which 76% come to the U.S.
<h1 class="wp-block-heading">The Deep Integration Of North American Auto Supply Chains</h1>
Decades of free trade have deeply integrated the automotive industries of the U.S., Canada, and Mexico. According to <a href="https://www.cato.org/blog/seven-charts-show-how-us-tariffs-would-harm-american-auto-industry#:~:text=Mexico%20and%20Canada%20Are%20the,%2C%22%20US%20International%20Trade%20Commission.">research </a>from the Cato Institute, Mexico and Canada together account for nearly half of U.S. imports and exports of motor vehicles and parts. 
This means that a tariff increase wouldn't just raise costs for American consumers and manufacturers — it could also trigger retaliatory actions from Mexico and Canada, potentially reducing U.S. car exports.
Also, vehicles assembled in Mexico often contain a high percentage of American-made components. A 2019 study found that nearly 74% of the foreign value-added in cars imported from Mexico came from the U.S. Another analysis from the Peterson Institute for International Economics estimated that 38% of the total value-added of vehicles imported from Mexico was American-made. If Mexico retaliates, this can spell bad news for the U.S. as well.
Simply put, slapping a 25% tariff on cars &#8220;made in Mexico&#8221; could inadvertently harm U.S. workers and businesses involved in supplying these vehicles. 
The stakes of the disruption of an already intertwined supply chain is quite high. Investors invested in such ETFs should keep a close eye on developments, and keep in mind that the tariffs could weigh heavy on the profitability of the underlying companies.
Read Next: 
<ul>
<li><a href="http://benzinga.com/economics/macro-economic-events/25/01/43398182/trumps-25-tariffs-could-slaughter-canada-mexico-economies-hit-us-auto-industry-analysts-warn">Trump&#8217;s 25% Tariffs Could Slaughter Canada, Mexico Economies, Hit US Auto Industry, Analysts Warn</a></li>
</ul>
Photo: Courtesy Ford Motor Co.

Government

Regulations

Sector ETFs

Global

ETFs

DRIV

FTXR

IDRV

STLA

3 U.S. Auto ETFs Caught In The Crosshairs As Trump Announces 25% Tariff On Mexican Imports

Editor&#8217;s Note: This article has been updated to correctly attribute the tariff announcement to the Trump administration.
U.S. equity indices reversed earlier gains and fell into negative territory during Friday afternoon trading in New York after the White House confirmed that new tariffs on imports from Canada, Mexico, and China would take effect on Saturday, escalating trade tensions with the <a href="https://www.benzinga.com/news/global/25/01/43401971/white-house-confirms-tariffs-on-key-us-trade-partners-this-weekend">country's three largest suppliers.</a>
The S&amp;P 500—tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)—fell 1%, sliding from 6,120 points at midday to 6,045 points by 2:45 p.m. ET.
The Dow Jones Industrial Average dropped 0.8% to 44,530 points, while the Nasdaq 100—tracked by the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)—fell 1.5%, reversing an earlier 1.3% gain.
Sector-wise, the Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) deepened its losses, sliding 2.9%. Meanwhile, the Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) was the only sector still in positive territory, up 0.3%, though it had pared earlier gains.
The Trump administration is imposing a 25% tariff on goods from Canada and Mexico, along with a 10% duty on Chinese imports. White House Press Secretary Karoline Leavitt stated that the measure responds to these nations&#8217; alleged role in allowing illegal fentanyl to enter the U.S.
A <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43398182/trumps-25-tariffs-could-slaughter-canada-mexico-economies-hit-us-auto-industry-analysts-warn">Goldman Sachs research note</a> published Friday estimated that GDP in Canada and Mexico could decline by 1% to 4%, with consumer prices rising up to 2% due to increased import costs.
For the U.S., the new tariffs would raise the overall tariff rate by 7.3 percentage points, resulting in a 0.7% increase in core personal consumption expenditures prices, the Federal Reserve's preferred inflation gauge, and a 0.4% drag on U.S. GDP growth.
<h3 class="wp-block-heading">Dollar Reigns Supreme, Canadian Dollar Nears 9-Year Lows</h3>
In currency markets, the U.S. dollar strengthened against all major counterparts, particularly against those most affected by the tariff announcement.
The greenback surged past 1.4520 against the Canadian dollar, on track to close the session at its highest level since January 2016.
The dollar erased earlier losses against the Mexican peso and gained 0.3% against the Chinese yuan.
A broader measure of dollar strength, as broadly followed by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), was up 0.3%.
<h3 class="wp-block-heading">Bond Yields Surge, Gold Retreats, Bitcoin Slumps</h3>
Treasury yields spiked, reflecting investor concerns over the inflationary impact of tariffs. Both 10-year Treasury yields and 30-year yields were up 5 basis points to 4.57% and 4.81%, respectively. 
As a reaction, the iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) fell 0.7%
Gold pared earlier gains amid a stronger dollar and rising yields.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) bore the brunt of the risk-off move, tumbling over 3% from $105,000 to $102,000.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43399315/apples-better-than-feared-guidance-calms-iphone-ai-china-concerns-7-analyst-reactions">Apple&#8217;s &#8216;Better Than Feared&#8217; Guidance Calms iPhone, AI, China Concerns: 7 Analyst Reactions</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Bonds

Broad U.S. Equity ETFs

Commodities

Currency ETFs

Econ #s

$BTC

iShares Trust Barclays 20+ Year Treasury Bond Fund

PowerShares DB US Dollar Index Bullish Fund

Wall Street Sinks On Trump's Tariff Announcement, Bitcoin Drops 3%, Dollar Soars (CORRECTED)

<a href="https://x.com/RJScaringe/status/1885426301437460517" title="https://x.com/RJScaringe/status/1885426301437460517">https://x.com/RJScaringe/status/1885426301437460517</a>

RIVN

Rivian Automotive Founder And CEO RJ Scaringe Posts On X "R2 expansion moving quickly!"

Wall Street analysts rerated Atlassian Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) and raised their price targets on the stock after its <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43355332/atlassian-q2-earnings-revenue-beat-eps-beat-strong-guidance-infusing-ai-and-more" rel="noreferrer noopener">upbeat quarterly print</a> Thursday.
<ul>
<li>JMP Securities analyst Patrick Walravens reiterated Atlassian with a <a href="https://www.benzinga.com/quote/TEAM/analyst-ratings" target="_blank" rel="noreferrer noopener">Market Perform</a>.</li>
<li>Raymond James analyst Adam Tindle maintained Atlassian with an Outperform and raised the price target from&nbsp;$250&nbsp;to&nbsp;$330.</li>
<li>Truist Securities analyst Joel Fishbein reiterated Atlassian with a Buy and raised the price target from&nbsp;$300&nbsp;to&nbsp;$350.</li>
<li>Keybanc analyst Jason Celino maintained Atlassian with an Overweight and raised the price target from&nbsp;$315&nbsp;to&nbsp;$365.</li>
<li>Cantor Fitzgerald analyst Thomas Blakey reiterated Atlassian with a Neutral and raised the price target from&nbsp;$264&nbsp;to&nbsp;$304.</li>
<li>Scotiabank analyst Nick Altmann maintained Atlassian with a Sector Perform and raised the price target from $250 to $330.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43315306/strykers-strategic-moves-impress-analysts-spine-implant-sale-and-nari-deal-set-to-drive-future-growth" target="_blank" rel="noreferrer noopener">Stryker&#8217;s Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth</a>
JMP Securities: Walravens rerated Atlassian after it reported better-than-expected fiscal second-quarter 2025 results. The company posted adjusted EPS of $0.96 (consensus $0.76) on total revenue of $1.286 billion (consensus $1.240 billion), reflecting 21% year-over-year growth, flat with last quarter.
Cloud revenue reached $847 million, up 30% year-over-year, well ahead of guidance of 25.5%. This marked a slight decline from 31% last quarter but exceeded the consensus estimate of 26%.
Data Center revenue totaled $362 million, increasing 32% year-over-year, down from 38% last quarter but surpassing the consensus of 28%.
Billings came in ahead of expectations at $1.470 billion (consensus $1.378 billion), representing 21% year-over-year growth.
Walravens projected third-quarter revenue of $1.35 billion and EPS of 88 cents.
Raymond James: Tindle rerated after Atlassian&#8217;s quarterly results that featured a continuation of elite Cloud growth at scale, and guidance above the analyst&#8217;s buy-side bogeys suggests durability. 
The analyst&#8217;s recent upgrade was predicated on a combination of macro indicators with a detailed NRR build that suggested Cloud growth could ultimately end closer to mid/high 20% than the initial low-20% guidance, which is materializing. 
An incremental focus on Enterprise customers provides both risk and opportunity as mid-market-focused tech companies attempting to grow in Enterprise can ultimately destroy unit economics and incremental capital investment. Tindle intends to monitor material changes in contribution margin but noted that initial customer acquisition tends to be costly. 
Atlassian has landed 85% of the Fortune 500, and this $14 billion opportunity unfolds alongside a new CRO with roots at SAP.
In the longer term, the AI opportunity Tindle spotlighted through sensitivity analysis on Rovo is gaining momentum, with 1 million+ monthly active users of Rovo and Atlassian Intelligence features. The analyst&#8217;s prior concern with Atlassian&#8217;s AI strategy was that it drove up customer acquisition cost (CAC) with an indeterminate impact on long-term value (LTV), meaning incremental customer economics were worsening. However, gross margin has continued to outperform, and Atlassian is showing incremental operating leverage during this ramp-up period.
The introduction of paid SKUs for AI has become an increased focus and a positive step toward the monetization of AI, which could be very meaningful over time with proper execution. This also has potential positive impacts on Atlassian&#8217;s valuation multiple, and Tindle noted little reason to make a valuation call here based on the longer-term potential.
Tindle projected third-quarter revenue of $1.35 billion and EPS of 92 cents.
Truist Securities: Atlassian&#8217;s second-quarter 2025 release delivered a substantial upside to Fishbein&#8217;s top and bottom line estimates. Atlassian called out stability in the SMB segments that had challenged the business in prior years, as well as traction with their enterprise sales motion and new product offerings. Fishbein noted that the company has established a solid foundation, and more can go right to drive upside to expectations through the year.
Fishbein projected third-quarter revenue of $1.35 billion and EPS of 90 cents.
Keybanc: Atlassian reported another strong quarter of Cloud and DC outperformance, driven by continued stabilization in SMB and paid seat expansions, solid enterprise execution, and migration activity. Significantly, the magnitude of the 2025 Cloud guidance raise to 26.5% (250 bps raise) was most impressive. 
Given the upcoming release of certain blockers (such as FedRAMP), the narrowing of feature/price gaps between DC and Cloud, and the improvement of enterprise motion, Celino noted that the momentum for Cloud is just getting started.
Celino projected third-quarter revenue of $1.35 billion and EPS of 91 cents.
Cantor Fitzgerald: Blakey&#8217;s rerating followed a solid fiscal second-quarter 2025 report and fiscal third-quarter outlook driven by strong Enterprise, AI, and pricing. Cloud revenue was partially driven by better-than-expected seat expansion and migrations, and seat expansion has also stabilized in SMB. 
The company reiterated its prudent posture on guidance, and Blakey noted that third-quarter 2025 Q/Q growth appears to be increasingly conservative. In addition to macro as a reason for conservatism, new CRO (January 2025) and strong &#8216;mega deals&#8217; in the fiscal second quarter could be additional reasoning around the fiscal third-quarter top-line guide.
Blakey projected third-quarter revenue of $1.35 billion and EPS of 91 cents.
Scotiabank: After a choppy start to software earnings season, Atlassian&#8217;s strong results stand out and likely provide investors with some comfort around software end market dynamics. Atlassian continues to post more significant upside to Cloud, though its prudent approach to guidance continues. 
Macro-wise, the company noted the environment was stable Q/Q, though seat expansion and migration activity exceeded expectations. Atlassian posted its best quarter of $1 million ACV deals and noted 1 million MAUs for its AI features and products. 
Ultimately, two clean quarters of Cloud upside and management leaving room for further upside in the second half should help the shares continue to work. Altmann is getting increasingly comfortable with the story and found the 40% Y/Y growth in Premium &amp; Enterprise and heightened Cloud adoption driven by Atlassian&#8217;s new AI capabilities, perhaps the most underappreciated aspect of the print.
Altmann projected third-quarter revenue of $1.35 billion.
Price Action: TEAM stock is up 13.1% at $310.95 at last check Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43314549/f5-sees-big-wins-in-multi-cloud-ai-security-and-it-refresh-analysts-forecast-more-upside" target="_blank" rel="noreferrer noopener">F5 Sees Big Wins in Multi-Cloud, AI Security, and IT Refresh, Analysts Forecast More Upside</a></li>
</ul>
Photo: Shutterstock

Price Target

Reiteration

Analyst Ratings

TEAM

Atlassian's Cloud Strength, AI Momentum, Enterprise Deals Impress Analysts

Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) has outperformed the market over the past 15 years by 1.96% on an annualized basis producing an average annual return of 14.25%. Currently, Encompass Health has a market capitalization of $9.91 billion. 
Buying $100 In EHC: If an investor had bought $100 of EHC stock 15 years ago, it would be worth $727.37 today based on a price of $98.41 for EHC at the time of writing.
<h3>Encompass Health's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738355711_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Encompass Health 15 Years Ago Would Be Worth This Much Today

Medicaid funding, totaling approximately $900 billion per year and serving around 72 million participants, and the 340B program <a target="_blank" href="https://www.benzinga.com/25/01/43294006/trump-white-house-blames-outage-for-medicaid-website-lockout-we-have-confirmed-no-payments-have-been-affected" rel="noreferrer noopener">are key focus areas for potential healthcare reforms.</a>
Goldman Sachs analyst Salveen Richter, however, warns that federal Medicaid cuts could lead to stricter policies and lower drug coverage.
Per Richter, the 340B program is currently facing increased scrutiny, with proposed reforms that could potentially benefit biopharma companies by limiting eligibility for drug discounts, which would enable &#8220;transfer of profits&#8221; from providers back to biopharma.
This shift could positively impact major biopharma companies with high exposure to 340B drugs, such as Merck &amp; Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) and Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>).
However, the specifics of these reforms are still uncertain, which could cause &#8220;volatility&#8221; in the healthcare sector until more details are released.
At the same time, Medicaid funding and eligibility changes are under consideration as potential cost-saving measures by the new administration.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43392796/abbvie-jumps-after-q4-earnings-beat-skyrizi-and-rinvoq-boom-offsets-humira-decline" rel="noreferrer noopener">AbbVie Jumps After Q4 Earnings Beat, Skyrizi And Rinvoq Boom Offsets Humira Decline</a>
These changes could have negative effects on biopharma companies with significant Medicaid drug exposure, including AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Gilead Sciences, and Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), whose top Medicaid drugs make up a large percentage of their US sales.
Overall, for the 340B program, the analyst sees potential policy/legal outcomes that would move dynamics towards a transfer of profits from providers to biopharma companies as a positive for much of the biopharma sector.
Meanwhile, potential Medicaid changes could create &#8220;potential headwinds&#8221; for healthcare providers and biopharma companies, though the exact effects remain uncertain.
The healthcare industry is awaiting further clarity on these proposed policy changes and their implications.
Overall, the analyst notes that exposure to Medicaid and 340B can vary widely by product and indication.
The top three highest-spend drugs for Medicaid (as of 2022) are AbbVie&#8217;s Humira, Gilead&#8217;s Biktarvy and Eli Lilly&#8217;s Trulicity for type 2 diabetes and cardiovascular disease.
For these drugs, Medicaid and 340B spending represented ~15-30% of the drugs' FY22 and FY23 revenue.
Further, 340B impact may vary for different methods of administration within the same indication &#8211; for example, Gilead&#8217;s expects lower 340B exposure for injectables for PrEP than for daily orals &#8211; and expansion of eligibility for 340B discounts may have an outsized impact on certain therapeutics over others.
Overall, 340B reform would serve as a tailwind to biopharma, as the aforementioned initiatives are generally intended to limit access to the statutory discount.
On the other hand, spending cuts to Medicaid could have a negative impact to volume if they have the effect of reducing coverage, the analyst writes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43308041/chevron-ge-vernova-engine-no-1-bet-big-on-ai-power-but-is-it-too-late" target="_blank" rel="noreferrer noopener">Chevron, GE Vernova Bet Big On AI Power: Data Centers To Consume Enough Natural Gas To Power 3.5 Million Homes</a></li>
</ul>

Movers

General

ABBV

GILD

Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts

Lemonade's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) short percent of float has risen 19.89% since its last report. The company recently reported that it has 16.85 million shares sold short, which is 32.43% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.05 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lemonade Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738355422_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lemonade has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Lemonade's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lemonade's peer group average for short interest as a percentage of float is 4.61%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

LMND

(LMND) - Analyzing Lemonade's Short Interest

Quantum-Si's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NYSE">QSI</a>) short percent of float has fallen 21.41% since its last report. The company recently reported that it has 18.59 million shares sold short, which is 18.21% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Quantum-Si Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738355417_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Quantum-Si has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Quantum-Si's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Quantum-Si's peer group average for short interest as a percentage of float is 6.13%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(QSI) - Analyzing Quantum-Si's Short Interest

Once upon a time, earning six figures was a badge of honor – a golden ticket that signified you'd made it into the upper class. But now? Not so much. Turns out, nearly a quarter of American workers – 21.1% or over 38 million people – earned at least $100,000 last year, according to DQYDJ.com.
That's a jaw-dropping number when you consider what six figures used to represent. But today, $100K isn't the luxury salary it once was. In fact, for many people, it's the bare minimum they believe they need to stop worrying about money altogether.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich-2">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
$100K: The New Baseline for Feeling "Okay"
Everything is more expensive now. So it's no surprise that a report from Edelman Financial Engines found 58% of Americans think earning $100K a year is necessary just to avoid worrying about everyday living expenses. For a quarter of respondents, even six figures doesn't cut it – they say at least $200K is needed to feel comfortable.
And they're not wrong. Inflation, skyrocketing home prices and rising interest rates have pushed living costs to extremes. What used to be a "dream salary" is now the starting point for many just to make ends meet – never mind saving for retirement, paying down debt or splurging on a vacation.
Trending: <a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a>&nbsp;
The Pressure Is Mounting
2024 has been another tough financial year for Americans, with inflation hammering household budgets and interest rates leaving <a href="https://www.benzinga.com/real-estate/24/11/41685300/1-in-13-homeowners-are-risking-it-all-heres-why-experts-call-it-a-huge-mistake">homeowners stuck in place</a>. It's no wonder money continues to be a top source of stress for families nationwide. And even with a six-figure salary, many workers are finding it hard to keep up:
• Housing costs are consuming larger chunks of paychecks than ever, with the median home price in the U.S. reaching $416,800 as of late 2024.
• Health care and child care<a href="https://www.benzinga.com/personal-finance/24/07/39778022/dave-ramsey-tells-man-and-wife-spending-80-000-a-year-in-child-care-costs-that-they-have-lost-th"> costs are skyrocketing</a>, putting even more pressure on families with young kids.
• The average American carries over $5,700 in credit card debt and interest rates punish anyone trying to pay it down.
When you add it all up, it's no wonder six figures barely feel enough to breathe.
Trending: Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.
Why It Doesn't Feel Like "Making It"
The truth is, six figures don't go as far as it used to and the data proves it. Here's why:
1. Inflation is Outpacing Wages
While $100K might look good on paper, it's worth <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42917321/consumer-inflation-worries-highest-since-2008-u-of-m-survey-says-wall-street-tumbles-to-2-month-lows">significantly less</a> than a decade ago. Prices on essentials like food, gas and housing have all surged, making it harder to stretch your paycheck.
2. Lifestyle Creep
<a href="https://www.benzinga.com/personal-finance/24/05/38945724/suze-orman-says-stop-wasting-your-money-on-things-designed-to-make-your-life-easier-warns-conven">Earning more often means spending more</a>, whether it's on a bigger home, better schools or just keeping up with rising living costs. That "extra" income disappears quickly.
3. Savings and Retirement Goals Are Higher
Americans now believe they need $1.46 million saved to retire comfortably, according to Northwestern Mutual – a 15% increase from the previous year. Even a six-figure salary doesn't leave enough room to hit those targets for many.
4. The Social Security Question
Younger generations are bracing for cuts to Social Security benefits by 2035, meaning they'll have to rely even more on personal savings – yet another stressor for the $100K crowd.
See Also: The average 401(k) balance soars to a record-breaking high – <a href="https://www.benzinga.com/money/average-401k-balances-soars-to-record-high">Here's how to know if your nest egg is keeping pace.</a>
The Bigger Picture
So, what's the takeaway? A six-figure salary might still sound impressive, but it's become the new baseline for millions of Americans. If you're in that group of workers making at least $100K a year, you might find it's just enough to tread water financially – not thrive.
If you want to make your dollar go further, now's the time to get strategic. <a href="https://www.benzinga.com/money/are-you-rich">Consulting a financial advisor</a> can help you create a plan to stretch your income, invest wisely and prioritize your goals. Whether building wealth, saving for retirement or tackling debt, having a clear road map can make all the difference in making six figures feel more than just the bare minimum.
Read Next:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li><a href="https://www.benzinga.com/money/suze-orman-retirement-bucket">&#8216;Which Bucket Do I Draw From First?&#8217; Suze Orman Explains To 67-Year-Old The Best Order For Tapping Into Her Retirement Accounts</a></li>
</ul>

Personal Finance

58% Of People Say $100,000 A Year Is The Bare Minimum To Avoid The Financial Stress Of Daily Life – Here's How Many Actually Earn This

Sprouts Farmers Market's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NYSE">SFM</a>) short percent of float has risen 5.42% since its last report. The company recently reported that it has 6.61 million shares sold short, which is 10.51% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.99 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Sprouts Farmers Market Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738355412_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Sprouts Farmers Market has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Sprouts Farmers Market's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Sprouts Farmers Market's peer group average for short interest as a percentage of float is 7.78%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(SFM) - Analyzing Sprouts Farmers Market's Short Interest

Goldman Sachs analyst Neil Mehta downgraded Magnolia Oil &amp; Gas Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGY#NYSE">MGY</a>) and Occidental Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>), while reinstating coverage on Expand Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>).
MGY: The analyst downgraded the company from Buy to Neutral and cut <a target="_blank" href="https://www.benzinga.com/quote/mgy/analyst-ratings" rel="noreferrer noopener">the price forecast from $27 to $26</a>.
Mehta writes that the bearish outlook reflects the company&#8217;s outperformance relative to peers.
This performance has been driven by effective cost improvement initiatives and a focus on capital efficiencies in 2024, along with its relatively low leverage, adds the analyst.
While he still anticipates strong operational execution, he believes the stock now reflects these advantages.
The analyst estimates MGY to maintain relatively flat production costs over the next two years as the majority of significant operational cost savings were realized through the company&#8217;s early 2024 cost-saving initiative.
OXY: Mehta downgraded the company from Neutral to Sell and cut <a href="https://www.benzinga.com/quote/oxy/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast from $54 to $45</a>.
The bearish outlook reflects the company's pause on capital returns to shareholders until meaningful balance sheet improvements are achieved. Additionally, while asset sales could support deleveraging, further clarity is needed on their scope and impact, adds the analyst.
Given the less attractive risk/reward profile, with an 8% downside compared to 25% upside for oil-focused peers, the analyst sees limited upside potential.
The analyst increased the estimated FCF yield from 10.0% to 11.0%, citing investors&#8217; growing emphasis on capital returns and the company&#8217;s higher leverage.
EXE: Mehta resumed coverage on the company with a Buy rating and price forecast of $121, <a target="_blank" href="https://www.benzinga.com/quote/exe/analyst-ratings" rel="noreferrer noopener">implying an 18% upside from current levels</a>.
The decision follows the merger of Chesapeake Energy (CHK) <a target="_blank" href="https://www.benzinga.com//node/41070109" rel="noreferrer noopener">and </a><a target="_blank" href="https://www.benzinga.com//node/41070109" rel="noreferrer noopener">Southwestern Energy (SWN)</a>.
The analyst writes that Expand Energy&#8217;s emphasis on capital efficiency, disciplined activity, and risk management strengthens confidence in its operational outlook.
While gas production growth from Haynesville is expected to support rising LNG export demand, the company&#8217;s dual-basin presence in Appalachia and Haynesville provides a low-cost core business in Appalachia with expansion potential in Haynesville, reducing basin takeaway constraints, adds the analyst.
Additionally, its flexible operational strategy offers strong long-term exposure to structural improvements in natural gas prices, says the analyst.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43382627" target="_blank" rel="noreferrer noopener">Chevron Q4 Earnings: Profits Decline Amid Lower Oil Output, Dividend Hike Offers Silver Lining</a></li>
</ul>
Photo: Shutterstock

Large Cap

Downgrades

Goldman Sachs Forecasts Limited Upside For Occidental & Magnolia: What's Next?

Purple Biotech (PPBT) has released an update. Purple Biotech announced positive results from its Phase 2 study of CM24 for pancreatic cancer, showi...

Purple Biotech's CM24 Shows Promising Cancer Results

Purple Biotech (PPBT) reported final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody tha...

Purple Biotech reports final results from randomized Phase 2 study of CM24

Purple Biotech soars on positive results from mid-stage trial of its pancreatic cancer treatment

Purple Biotech (PPBT) has entered into a definitive agreement for the purchase and sale of 472,668 of the Company's American Depositary Shares, eac...

Purple Biotech to sell 472,668 ADSs at $6.00 in registered direct offering

Purple Biotech shares fall on $2.8M direct offering of ADS

Purple Biotech (PPBT) has released an update. Purple Biotech has announced a $2.8 million registered direct offering of American Depositary Shares,...

Purple Biotech Secures $2.8 Million Through ADS Offering

Purple Biotech (PPBT) has released an update. Purple Biotech Ltd., an Israeli company, has entered into a Securities Purchase Agreement to issue an...

Purple Biotech Signs Securities Purchase Agreement

Purple Biotech (PPBT) has released an update. Purple Biotech has successfully closed a $2.8 million registered direct offering of American Deposita...

Purple Biotech Secures $2.8 Million for Oncology Advancements

Purple Biotech (PPBT) has released an update. Purple Biotech, listed on NASDAQ/TASE as PPBT, is advancing its clinical-stage oncology drugs, CM24 a...

Purple Biotech Advances Oncology Drugs with New Funding

An announcement from Purple Biotech ( ($PPBT) ) is now available. Purple Biotech Ltd. has announced an adjustment to its existing at-the-market (AT...

Purple Biotech Expands ATM Offering by $1.33 Million

PPBT

Press Releases

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Health Care

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Comments

Purple Biotech

ニュース

最新ニュース Purple Biotech (NASDAQ:PPBT) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル